结缔组织病相关间质性肺疾病的管理
Management of connective tissue disease-associated interstitial lung disease.
作者信息
Chartrand Sandra, Fischer Aryeh
机构信息
Department of Medicine, National Jewish Health, University of Colorado School of Medicine, 1400 Jackson Street, Denver, CO 80206, USA; Department of Medicine, Rheumatology Clinic, Hôpital Maisonneuve-Rosemont, Université de Montréal, 5415 Boulevard de l'Assomption, Montréal, Québec H1T 2M4, Canada.
Department of Medicine, National Jewish Health, University of Colorado School of Medicine, 1400 Jackson Street, G07, Denver, CO 80206, USA.
出版信息
Rheum Dis Clin North Am. 2015 May;41(2):279-94. doi: 10.1016/j.rdc.2015.01.002. Epub 2015 Feb 3.
A thorough, often multidisciplinary assessment to determine extrathoracic versus intrathoracic disease activity and degrees of impairment is needed to optimize the management of connective tissue disease (CTD)-associated interstitial lung disease (ILD). Pharmacologic intervention with immunosuppression is the mainstay of therapy for all forms of CTD-ILD, but should be reserved for those that show clinically significant and/or progressive disease. The management of CTD-ILD is not yet evidence based and there is a need for controlled trials across the spectrum of CTD-ILD. Nonpharmacologic management strategies and addressing comorbidities or aggravating factors should be included in the comprehensive treatment plan for CTD-ILD.
为了优化结缔组织病（CTD）相关间质性肺病（ILD）的管理，需要进行全面的、通常是多学科的评估，以确定胸外与胸内疾病活动度及损伤程度。免疫抑制的药物干预是所有形式的CTD-ILD治疗的主要手段，但应仅用于那些表现出具有临床意义和/或进展性疾病的患者。CTD-ILD的管理尚无循证依据，需要针对整个CTD-ILD范围开展对照试验。非药物管理策略以及处理合并症或加重因素应纳入CTD-ILD的综合治疗计划。
Zotero 插件